ScripScrip regularly covers business development and deal making in the biopharmaceutical industry. Deal Watch is supported by deal intelligence from Biomedtracker. Organon Will Market Lilly’s Emgality, R
ScripFaron Pharmaceuticals Oy has seen its stock jump after the Finland-headquartered group identified a subgroup of respiratory distress syndrome (ARDS) patients from a failed late-stage trial who may be
ScripCara Therapeutics Inc. got a vote of confidence for its Phase III pruritis candidate Korsuva (CR845/difelikefalin) in a deal that licenses ex-US commercial rights to the drug to Vifor Fresenius Me
ScripFaron Pharmaceuticals is in turmoil after its lead drug Traumakine (interferon-beta 1a) failed in a pivotal Phase III trial; the company awaits full data from the INTEREST study but the future look